MedTrace Logo

Isotretinoin for Proliferative Vitreoretinopathy

NCT01445028 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2018-06-01

Study results available
· View outcomes & findings →

Summary

Proliferative vitreoretinopathy (PVR), or secondary scarring on and around the retina, is an important cause of retinal re-detachment. The purpose of this study is to evaluate the effect of oral isotretinoin, which inhibits the growth of cells responsible for proliferative vitreoretinopathy (PVR), on recurrent retinal detachment.

Conditions

  • Proliferative Vitreoretinopathy

Interventions

DRUG

Isotretinoin

Isotretinoin 20mg daily for 12 weeks

Sponsors & Collaborators

  • Wills Eye

    lead OTHER

Principal Investigators

  • Richard S Kaiser, MD · Wills Eye Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-08-31
Completion
2015-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01445028 on ClinicalTrials.gov